STERIS submissions selected as part of FDA innovation challenge

June 2, 2020

In July 2019, the U.S. Food and Drug Administration (FDA) announced two innovation challenges to encourage the development of new approaches to contract sterilization of single-use medical devices. On November 25, 2019, the Agency announced that 46 applications were received as part of the challenge and 13 were selected.

STERIS is excited to announce that all three of its applications were accepted by the FDA and, as a result, will work with the Agency to accelerate the development and review of innovative technologies.

 About the Innovation Challenges

The innovation challenges were developed to encourage ideas from academics, industry and others about novel solutions for improving processes used for the contract sterilization of single-use medical devices.

  •  Challenge one: Identify alternatives to ethylene oxide sterilization methods
  • Challenge two: Develop strategies to reduce ethylene oxide

 STERIS Applications

STERIS Applied Sterilization Technologies (AST) submitted three proposals as part of the challenge:

  • Sustainable EO® Sterilization Services (challenge two)
  • Terminal Sterilization of Medical Devices Using Accelerator-Based Technology (challenge one)
  • Terminal Sterilization of Medical Devices Using Vaporized Hydrogen Peroxide (challenge one)

Go here to learn more about our global contract sterilization and microbial reduction services using a technology-neutral offering of radiation and gas technologies.

STERIS_AST_Logo

About STERIS

STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life sciences products and services. For more information, visit www.steris.com.

 
Related Posts
Exterior View of STERIS Facility in Batu Kawan, Malaysia
May 1, 2025

1st May, 2025 As part of our long-term commitment to supporting global medical device manufacturing, STERIS is pleased to announce a new ethylene oxide (EO) processing facility in Batu Kawan industrial Park in Penang, Malaysia.

202310-LibertyvilleIL-Lab-5
March 28, 2025
March 28, 2025 – As part of our long-term commitment to supporting medical device and pharmaceutical manufacturing, STERIS Applied Sterilization Technologies (AST) is pleased to announce the addition of Extractables and Leachables (E&L) testing, featuring advanced chemical analysis.
New-Swindon-Lab-1-600x600
February 5, 2025
February 5, 2025 – As part of our long-term commitment to supporting medical device and pharmaceutical manufacturing, STERIS is pleased to announce our South Marston, UK laboratory has relocated to Swindon, UK. The new laboratory supports the increased demand in volume and complexity of medical devices and pharmaceuticals in the region.
STERIS is pleased to announce our brooklyn park mn usa laboratory now offers bacteria
January 10, 2025
January 10, 2025 – As part of our long-term commitment to supporting global healthcare product manufacturing, STERIS is pleased to announce our Brooklyn Park, Minnesota, USA laboratory now offers a sustainable approach to bacterial endotoxin testing through the use of recombinant cascade reagents.